Navigation Links
Regular Eye Screens Spot Diabetic Vision Trouble
Date:9/25/2007

Chronic high blood sugar is leading cause of adult-onset blindness, experts note

TUESDAY, Sept. 25 (HealthDay News) -- Diabetics are more likely to get their vision checked if they have access to health care, as well as information about why those screenings are important, experts say.

However, minorities with diabetes or people living in rural areas are still less likely to get screened, even when they know why it is important to do so.

Vision screenings can help prevent retinopathy, a progressive degeneration of the retina which is a complication of diabetes. The small blood vessels of the eye can become damaged by years of high blood sugar levels.

In its early stages, a person with diabetes may experience no symptoms or only a mild blurring of their vision. But, as vision trouble progresses, people begin to see spots or "floaters" in their field of vision. Diabetes is the leading cause of adult-onset blindness in the United States. Managing blood sugar levels and blood pressure levels can help prevent diabetic retinopathy.

The American Diabetic Association recommends that people with diabetes get an eye check with dilation every year. Only 47 percent of diabetics get their annual vision check, according to the most recent data.

The importance of educating patients and doctors about vision screenings is highlighted in research published in the October issue of the American Journal of Preventive Medicine. The study analyzed data from 48 studies focused on efforts to increase the awareness of vision screenings among diabetics. The data came from more than 160,000 participants from the United States, Australia, the United Kingdom, Israel, Saudi Arabia and other countries.

"In all randomized controlled trials but one, interventions achieved statistically significant increases in retinal screening rates in the intervention group compared to the control group," lead researcher Xuanping Zhang
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Startling Expose – Physicians Often Have No Regular Source Of Health Car
2. Regular exercise prevents hip fractures
3. Irregular Periods Linked to Diabetes
4. Diet irregularities lead to stomach cancer
5. Osteoporosis could be caused by irregular periods
6. Regular exercise linked to extended menstrual cycles
7. Hypertensives could benefit regular alcohol consumption
8. Obesity risk can be reduced by eating breakfast regularly
9. Switching drugs regularly improves HIV treatment
10. New Test To Detect Irregular Heartbeats
11. Identifying Irregular Heart Beats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2008)...f a partial blockage last fall , , SATUR... Edward M. Kennedy was taken from a local hospital...assachusetts General Hospital in Boston early Satu...d possibly a second one, according to news reports... hospital, according to an early afternoon news re...
(Date:5/17/2008)...ather to tell motorists ,Click It or Ticket ...hoolers display art and videos promoting seat belt...t: Local kickoff of the 2008 "Click It or Ticket... Monday, May 19, 2008 Noon (free buffet l...here: The Cleveland House of Blues 308 E...
(Date:5/16/2008)...ire/ -- In the aftermath of central China,s,earthq... their lives, and,over 150,000 were injured. An es... 4 million who have lost their homes. With great s...upreme Master Ching Hai donated an,additional US$3...s from,Supreme Master Ching Hai International Asso...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
Breaking Medicine News(10 mins):Health News:Sen. Edward Kennedy Hospitalized After Seizure 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2
... Christopher Moir at Minnesota's Mayo Clinic has s...ns from Bismarck, North Dakota// (ND) and now they...r chest walls. Abygail and Madysen Fitterer, the ...uzy Fitterer and who were born joined at the chest...
...on's appear to increase the risk of heart valve di...a degenerative disorder of the central nervous sys...eart valves are one-way valves that keep blood flo... through the heart. If people have problems with t...
...nce that suggests a link between a particular gene...x infection//. The journal, Neurobiology of Aging,...individuals, the same gene is implicated in causin... is of much interest to the scientific world. It r...
...s received tentative approval from the US Food and...rtraline Hydrochloride for// treatment of major de... Hydrochloride tablets will be the AB-rated generi...loft tablets of 25mg, 50mg and 100mg dosage. "Th...
Other Medicine News:Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4
(Date:5/16/2008)...at ASCO Annual Meeting Will Further Demonstrate, ...e Multiple Myeloma -, CAMBRIDGE, Mass., May 16 /P...da Oncology Company, today announced that new data... featured at the 2008 American Society,of Clinical...is, May 30 -,June 3, 2008. The data will highlight...
(Date:5/16/2008)... industry and customer thought leaders -, SAN FRA...cognized,leader and trusted resource for clinical ...llation of prestigious academic medical centers, r...annual user group meeting in San,Francisco. The Ve...y and,collaboratively manage thousands of clinical...
(Date:5/16/2008)...- Results demonstrating that TYKERB and trastuzuma...ension of progression-free survival (PFS), -- Com...nside and,outside of the HER2 receptor may create ...ing activity of TYKERB alone despite patients,pre... and chemotherapy, LONDON and PHILADELPHIA, May 1...
(Date:5/16/2008)...- Veridex, LLC announced today that,i...of America Holdings,(LabCorp), has commercially la...ncer. The new assay uses the biological specificit...ng the methylation of the gene,GST-Pi. Methylation...,cancer. Veridex is developing the methylation mar...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 1Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 2Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 3Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 4Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 5Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 6Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 7Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 8Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 9Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 10Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 11Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 12Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 13Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 14Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 15Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 16Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 17Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 18Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 19Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 20Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 21Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 22Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 23Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 24Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 25Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 26Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 27Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 28Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 29Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 30Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 31Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 32Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 33Dr Mark Nestor Presents on Pyratine 6 28TM 29 at the South Beach Symposium 3440 1Dr Mark Nestor Presents on Pyratine 6 28TM 29 at the South Beach Symposium 3440 2Dr Mark Nestor Presents on Pyratine 6 28TM 29 at the South Beach Symposium 3440 3Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 1Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3
...ity, a Novel Mechanism,of Action and In Vitro Comp...onn., April 16, 2007 /PRNewswire-FirstCall/ --,Ach...resentation of,data validating the clinical antivi...s, ACH-806, for the treatment of,hepatitis C virus...,European Association for the Study of the Liver (...
... ProNAi Therapeutics,Inc., a biopharmaceutical co... based on DNA interference (DNAi), today,announced...2258,has successfully demonstrated preclinical in...uman cancers - including curative,events for diffi...Gill, President and CEO of ProNAi, said, "Team,Pro...
Other Medicine Technology:Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma 2
...sthesia and Respiratory Products, ,Westmed design...al devices for Anesthesia and Respiratory professi...oducts that enhance the clinician's ability to del...tion to the bottom line. , ,Our web site is desig...
...sthesia and Respiratory Products, ,Westmed design...al devices for Anesthesia and Respiratory professi...oducts that enhance the clinician's ability to del...tion to the bottom line. , ,Our web site is desig...
... medication nebulizer achieves optimum lung penetr...MMAD particle size range is 1.04-1.10 µ at 6...sor or air outlet., ,As the world leader in airwa...oviders the assurance of proven technology by offe...
... medication nebulizer achieves optimum lung penetr...MMAD particle size range is 1.04-1.10 µ at 6...sor or air outlet., ,As the world leader in airwa...oviders the assurance of proven technology by offe...
Medicine Products: